Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Phase 3
496
about 3.1 years
18+
Female only
103 sites in AL, AR, AZ +36
What this study is about
Researchers are testing a treatment called ubrogepant for menstrual migraine. The trial is testing how safe and effective ubrogepant is in treating menstrual migraine. Participants will take either ubrogepant or a placebo daily for 16 weeks, then may continue with ubrogepant for another 52 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo for Ubrogepant
- 2.Take Ubrogepant
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ubrogepant
oral (Oral Tablet)
Primary: Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period, Number of Participants With Adverse Events (AEs)
Secondary: Change From Baseline in Acute Medication Use Days During the Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period, Change From Baseline in Number of Headache Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period, Change From Baseline in Number of Migraine Days With Moderate or Severe Headache During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period, Change From Baseline in Number of Moderate or Severe Headache Days During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period
Neurology